Fertility Testing in Torrance: A Complete Guide to the Infertility Workup and Pre-IVF Screening

By the Incinta Editorial Team · Medically reviewed by the Incinta Review Team

Before any fertility treatment is chosen, there is a quieter and more important step: finding out why pregnancy has not happened yet. That step is called the infertility workup or fertility evaluation, and it is a structured series of tests for both partners rather than a single blood draw. Patients in Torrance and across the South Bay often arrive at a first consultation expecting to discuss IVF immediately, and are surprised to learn that a well-designed workup may point toward a much simpler answer — or toward a treatment plan that looks quite different from the one they assumed.

This guide explains what a complete evaluation typically includes, why each test is ordered, what the results can and cannot tell you, and how findings translate into a decision between timed intercourse, IUI, and IVF. It is written for people who are just starting to ask questions as well as for those who have already had scattered tests elsewhere and want to understand how the pieces fit together. It complements our complete guide to IVF in Torrance, which covers treatment itself rather than the diagnostic phase that comes first.

Two framing points matter from the outset. First, infertility is common: the WHO estimates that approximately one in every six people of reproductive age worldwide experience infertility in their lifetime. Second, a workup is not a hunt for someone to blame. It is an information-gathering exercise whose value is measured by how much it changes the plan — and a test that will not change the plan is usually not worth doing.

1. Why the Workup Comes Before Treatment

Treatment without a diagnosis is guesswork, and in fertility care guesswork is expensive in both money and time. A couple with blocked fallopian tubes will not conceive with ovulation-induction medication alone; a couple whose only issue is a severe sperm abnormality will not benefit from repeated intrauterine insemination; a person with diminished ovarian reserve may need a very different timeline than someone with polycystic ovary syndrome and irregular ovulation. The same headline treatment can be the right answer for one of these situations and the wrong answer for another.

A workup also establishes a baseline. Female hormone results are cycle-day dependent, antral follicle counts vary between observers and ultrasound machines, and semen parameters fluctuate substantially from one sample to the next. Documenting results before medication starts makes it possible to interpret later changes — for example, distinguishing a genuinely low ovarian response from a single unusual cycle. It also identifies health issues that should be addressed before pregnancy: thyroid disease, uncontrolled diabetes, immunity gaps, medication teratogenicity, or a uterine cavity abnormality that would raise miscarriage risk.

Finally, a complete evaluation protects patients from overtreatment. ACOG’s patient FAQ on evaluating infertility frames the first visit as a history, examination, and a defined set of tests — not an open-ended menu of add-ons. When a clinic proposes a long list of specialised assays before the basic questions have been answered, it is reasonable to ask which decision each test will change. That question is the simplest way to separate an evidence-based workup from an unnecessarily expensive one.

2. When to Seek a Fertility Evaluation: The 12 / 6 / 3 Rule

Timing is the first clinical decision, and it is based mainly on age. The conventional rule is easy to remember:

• Under 35: seek an evaluation after 12 months of regular, unprotected intercourse without pregnancy. This matches the WHO and NICHD definitions of infertility.
• 35 to 39: seek an evaluation after 6 months. NICHD explicitly shortens the interval to six months when the woman is older than 35, because the window for both natural conception and treatment narrows.
• 40 and older: do not wait for a full six months. Many specialists recommend evaluation within roughly three months of trying, and ASRM practice guidance emphasises prompt assessment in this group. Our Age and Fertility in Torrance guide explains the biology behind the shorter timeline.

There is also a set of situations in which waiting is not appropriate at any age. These include absent or very irregular menstrual periods, a known or suspected tubal blockage, a history of pelvic inflammatory disease or ectopic pregnancy, diagnosed moderate-to-severe endometriosis, two or more pregnancy losses, known male-factor issues such as chemotherapy or undescended testes, prior cancer treatment, or a partner who has had a vasectomy. Recurrent miscarriage has its own distinct evaluation, covered in our Recurrent Pregnancy Loss in Torrance guide; NICHD notes that recurrent pregnancy loss is considered distinct from infertility, even though the two can overlap.

One nuance worth stating plainly: the 12-month rule is a threshold for investigation, not a guarantee that nothing is wrong before then, and not a deadline that must be endured. If you have a specific concern, an earlier conversation is reasonable. Conversely, reaching 12 months does not mean something is definitively broken — most couples evaluated at that point still go on to conceive, and the workup often finds no single dramatic cause.

3. The Pre-IVF Testing Checklist: What a Complete Workup Covers

The following numbered checklist is the practical summary of a standard evaluation. Not every item applies to every person, and the order depends on the menstrual cycle, but this is the set of domains a clinician will usually want to have covered before recommending IVF.

1. A full reproductive history for both partners — cycle pattern, prior pregnancies and losses, contraception, surgeries, infections, medications, occupational exposures, and family history.
2. Ovarian reserve testing — AMH, antral follicle count on transvaginal ultrasound, and often cycle-day 2–4 FSH with estradiol.
3. Confirmation of ovulation — mid-luteal serum progesterone, urinary LH kits, or cycle tracking where cycles are irregular.
4. Tubal patency assessment — hysterosalpingography (HSG) or a contrast-enhanced ultrasound alternative.
5. Uterine cavity assessment — transvaginal ultrasound, saline infusion sonohysterography, or hysteroscopy when indicated.
6. Semen analysis — performed early, with a repeat sample if the first is abnormal; this is the single highest-yield first test for the male partner.
7. Hormonal and metabolic panel — TSH, prolactin when indicated, and androgens or glucose/insulin testing where PCOS or metabolic risk is present.
8. Infectious disease and immunity screening — required before any ART cycle, and useful preconception generally (rubella, varicella, hepatitis B and C, HIV, syphilis, and blood type with Rh factor).
9. Genetic carrier screening — offered to both partners, with counselling about residual risk and what a negative result does not exclude.
10. Preconception review — folic acid, current medications, vaccinations, and chronic-condition control.
11. A results consultation that produces a written plan, including what remains unexplained and which findings would change the plan.

Notice what is not on the list: immune panels, thrombophilia screens in people without a relevant history, endometrial receptivity arrays, sperm DNA fragmentation assays, and routine diagnostic laparoscopy. These are sometimes discussed in specific circumstances, but they are not part of a standard first-line workup; ASRM Practice Committee documents and ACOG guidance caution against tests whose results do not reliably change management. Section 12 returns to this.

4. The First Appointment: History, Examination, and What to Bring

Most of the diagnostic value in a first visit comes from the conversation. A clinician will ask about menstrual regularity, the length and variability of cycles, any prior pregnancies or losses, previous contraception, pelvic surgery, sexually transmitted infections, endometriosis symptoms, thyroid or autoimmune disease, cancer treatment, and medications including supplements. For the male partner, relevant history includes varicocele, hernia or testicular surgery, undescended testes, infections such as mumps orchitis, heat and occupational exposures, anabolic steroid use, and ejaculatory or erectile issues. ACOG describes the first visit in exactly these terms.

A physical examination may follow, and a transvaginal ultrasound is commonly performed at or near the first visit because it gives immediate information about uterine anatomy, fibroids, ovarian appearance, and antral follicle count. ACOG’s FAQ specifically addresses imaging tests, basal body temperature tracking, urine LH testing, progesterone testing, and thyroid testing as components of the basic evaluation.

To make the appointment efficient, bring:

• A menstrual calendar or app export covering at least the last three to six cycles.
• Any prior test results — hormone panels, ultrasounds, HSG reports and images, semen analyses, operative reports, and pathology from prior losses or surgery.
• A current medication and supplement list with doses, including over-the-counter products.
• Vaccination and immunity records if available, and any known drug or contrast allergies.
• Insurance information and questions about coverage, since diagnostic testing and treatment are frequently covered differently.
• A written list of questions. ACOG notes that infertility testing is not always covered by insurance, so ask before scheduling rather than after receiving a bill.

5. Ovarian Reserve Testing: AMH, FSH, Estradiol, and Antral Follicle Count

Ovarian reserve testing estimates the quantity of the remaining oocyte pool. It is one of the most useful parts of the workup and also one of the most frequently misinterpreted, so it is worth being precise about what each marker does.

AMH (anti-Müllerian hormone)

AMH is produced by small growing follicles and can be measured on any day of the cycle, which makes it convenient. It correlates reasonably well with the number of eggs retrieved in an IVF stimulation cycle, so it is genuinely useful for planning medication dosing and anticipating response. But AMH is a marker of quantity, not quality, and a low value alone does not establish that natural conception is impossible. Our dedicated AMH and Ovarian Reserve in Torrance guide covers assay variability, typical reference ranges, and why AMH should not be used as a standalone verdict on fertility.

Antral follicle count (AFC)

AFC is the number of small resting follicles visible on transvaginal ultrasound in the early follicular phase. It is measured at the same time as the baseline scan and provides an independent cross-check on AMH. AFC is operator- and equipment-dependent, so results from different clinics are not always directly comparable.

FSH and estradiol (cycle days 2–4)

Baseline FSH rises as ovarian reserve declines, but it must be interpreted alongside estradiol, because a high estradiol can suppress FSH into an apparently normal range. FSH also varies between cycles. In practice, most clinicians now lean on AMH plus AFC and use FSH as supporting information rather than the primary number.

6. Confirming Ovulation: Progesterone, LH Kits, and Cycle Tracking

If cycles are regular and predictable, ovulation is usually occurring, and extended confirmation may add little. When cycles are irregular, long, or absent — as with PCOS — establishing whether and when ovulation happens becomes central to the plan.

• Mid-luteal serum progesterone: a blood test timed to roughly seven days before the expected period. ACOG describes the progesterone test as part of basic testing. A single value confirms that ovulation likely occurred in that cycle; it does not grade egg quality or guarantee a receptive endometrium.
• Urinary LH kits: detect the mid-cycle LH surge and are useful for timing intercourse or insemination. They can be misleading in PCOS, where LH tone may be elevated, and they predict rather than confirm ovulation.
• Basal body temperature tracking: ACOG addresses its purpose in the basic evaluation. It is retrospective, low-cost, and vulnerable to sleep and illness artifacts; many clinics no longer rely on it as a primary tool.
• Ultrasound monitoring: in a monitored cycle, serial scans track follicle growth and confirm collapse of the dominant follicle. This is the most direct method, but also the most resource-intensive.

The interpretive boundary here is important. Confirming ovulation tells you an egg was released; it does not tell you about the tube that must pick it up, the sperm that must reach it, or the cavity where an embryo would implant. That is why ovulation testing sits alongside — never instead of — the other domains in the checklist.

7. Tubal Patency: HSG, Contrast Ultrasound, and What They Cannot Show

The fallopian tubes cannot be assessed with a standard ultrasound or a blood test. Hysterosalpingography, or HSG, is the conventional first-line study: contrast dye is passed through the cervix under X-ray imaging, outlining the uterine cavity and showing whether dye spills freely from both tubes. MedlinePlus describes HSG as a special X-ray using dye to look at the womb and fallopian tubes, performed in the first half of the menstrual cycle.

HSG is genuinely informative, but it has real limits that patients should know before consenting:

• Discomfort: cramping during and after the procedure is common, similar to menstrual cramps; MedlinePlus notes discomfort from speculum insertion and possible pain if dye leaks or tubes are blocked.
• Contrast and radiation: there is a small risk of allergic reaction to contrast and a low-dose radiation exposure. Tell your provider about prior contrast reactions.
• Infection risk: endometrial or tubal infection and, rarely, uterine perforation are listed risks; the test is not performed in the presence of active pelvic inflammatory disease or unexplained vaginal bleeding.
• False positives: proximal tubal spasm can make a normal tube appear blocked. A reported blockage near the uterine corner sometimes warrants a second look rather than an immediate move to IVF.
• Blind spots: HSG shows the cavity and tubal outline, not endometriosis, adhesions outside the tubes, or ovarian pathology.

Contrast-enhanced ultrasound (HyCoSy) avoids ionising radiation and can be performed in the clinic, but it is more operator-dependent and gives less detailed tubal anatomy. Saline infusion sonohysterography excels at the uterine cavity but does not reliably assess the tubes; hysteroscopy and laparoscopy are reserved for specific indications because they are invasive. When a workup does find tubal disease, our Tubal Factor Infertility in Torrance guide explains how the finding changes the decision between surgery, IUI, and IVF.

8. The Uterine Cavity: Ultrasound, Sonohysterography, and Hysteroscopy

A transvaginal ultrasound is the starting point for uterine assessment. It identifies gross anatomy, adenomyosis features, and most clinically meaningful fibroids, but it can miss small intracavitary polyps, submucosal fibroids, a uterine septum, or intrauterine adhesions — precisely the lesions that most affect implantation and miscarriage risk.

Saline infusion sonohysterography, in which sterile fluid is introduced into the cavity during ultrasound, separates the endometrial surfaces and makes these lesions visible without radiation. Hysteroscopy goes one step further, allowing direct visualization and, in many cases, immediate treatment. Both are typically ordered when the baseline scan is abnormal, when there is abnormal uterine bleeding, when pregnancy losses have occurred, or before an embryo transfer in a cycle where the cavity has not been clearly documented.

The trade-off is invasiveness versus certainty. Ultrasound is painless and repeatable but least sensitive; sonohysterography is minimally invasive with a brief cramping discomfort and a small infection risk; hysteroscopy is the most definitive and, in some settings, therapeutic, but it is a procedure with anaesthesia and surgical considerations. Our Uterine Fibroids and Fertility in Torrance guide discusses specifically which fibroid types justify removal and which do not — a distinction that matters because operating on a fibroid that does not distort the cavity has not been shown to improve fertility outcomes.

9. Semen Analysis: The Highest-Yield First Test for the Male Partner

Male factors contribute to a large share of infertility — MedlinePlus states that about half of couples unable to have children have a male infertility problem, and the WHO explicitly lists male, female, and unexplained factors as the three categories. Yet the male evaluation is still sometimes left until after months of female testing. A semen analysis is non-invasive, inexpensive relative to treatment, and should be one of the very first tests ordered.

The test evaluates semen volume, sperm concentration, motility, morphology, viscosity, pH, and fructose content, and checks for white blood cells that might suggest infection. Collection details materially affect the result: MedlinePlus recommends two to three days without ejaculation before collection (and not longer than five days), delivery of the sample to the laboratory within about 30 minutes while kept near body temperature, and analysis within two hours.

Because a single sample varies with illness, fever, heat exposure, stress, and abstinence interval, an abnormal result is usually repeated, commonly after an interval that reflects the roughly two-to-three-month sperm production cycle. If a severe abnormality or azoospermia is confirmed, the workup extends to hormonal testing (FSH, LH, testosterone), physical examination by a urologist, and targeted genetic testing. Our Male Infertility and ICSI in Torrance guide explains those next steps and when ICSI becomes part of the IVF plan. Lifestyle factors that affect sperm parameters — smoking, alcohol, heat, and anabolic steroids — are covered in our Nutrition and Lifestyle for Fertility guide.

10. Hormonal and Metabolic Screening: TSH, Prolactin, Androgens, and Glucose

Thyroid-stimulating hormone is a standard part of the basic evaluation; ACOG specifically explains why a thyroid function test is ordered. Both overt hypothyroidism and hyperthyroidism can disrupt ovulation and are associated with adverse pregnancy outcomes, and thyroid disease is common enough in this population that screening is efficient.

Prolactin is checked when cycles are irregular, when there is galactorrhea, or when ovulation is absent, rather than universally. Androgen testing (total and free testosterone, DHEAS) and glucose/insulin assessment are targeted to people with signs of hyperandrogenism, irregular cycles, or polycystic ovary morphology. PCOS and Fertility in Torrance covers how those results feed into ovulation induction and metabolic management.

The balance here is against indiscriminate panels. A broad hormone battery in a person with regular ovulatory cycles and a normal examination rarely changes management. Conversely, missing a treatable thyroid abnormality can waste months of otherwise appropriate treatment. Targeted testing, directed by history and examination, is the middle path recommended in ASRM practice guidance.

11. Infectious Disease, Immunity, and Genetic Carrier Screening

Some screening is about the safety of a future pregnancy rather than the cause of infertility. Rubella and varicella immunity can be checked and vaccination updated before conception; blood type and Rh status matter for prenatal care. Before any assisted reproduction cycle, clinics also require infectious disease screening for both partners — typically hepatitis B and C, HIV, and syphilis — under regulatory and laboratory standards. CDC’s ART overview describes the national framework in which ART is performed and reported in the United States.

Genetic carrier screening is offered to both partners regardless of family history for a panel of recessive conditions. ACOG’s Carrier Screening FAQ explains who should be offered screening and how to interpret results. Two points deserve emphasis. First, a negative screen reduces but does not eliminate residual risk, because no panel covers every variant or every condition. Second, finding that both partners carry the same recessive condition does not mean pregnancy is impossible; it opens a conversation about genetic counselling, prenatal diagnosis, and — in some cases — PGT in Torrance, which is a separate decision with its own indications and limitations.

Preconception supplementation belongs in the same conversation. CDC recommends that people who could become pregnant consume 400 micrograms of folic acid daily to help prevent neural tube defects, and MedlinePlus provides a broader Patient-facing overview of nutrition in pregnancy. Our Nutrition and Lifestyle for Fertility in Torrance guide covers the evidence behind supplements in more depth, including where the evidence is weak.

12. Tests That Are Not Part of a Routine Workup — and Why

A responsible guide should also say what a good workup does not include. Fertility care has a well-known problem with add-on tests and adjuncts marketed directly to patients who are understandably anxious and willing to try anything. ASRM Practice Committee documents and ACOG’s Treating Infertility FAQ both emphasise that a test should be ordered only when its result will change a decision.

• Routine immune panels and natural-killer-cell testing: not recommended as first-line investigation. Immunologic explanations for implantation failure and recurrent loss remain an area of active research, and the proposed treatments carry cost and risk without demonstrated benefit in unselected patients. Our RPL guide sets out the evidence and the grey areas in detail.
• Thrombophilia screening without a relevant history: may be appropriate after recurrent pregnancy loss or a personal/family history of thrombosis, but is not a standard infertility screen.
• Endometrial receptivity arrays and routine ERA testing: not recommended for all patients; evidence that they improve live-birth rates in unselected populations is insufficient.
• Sperm DNA fragmentation testing: may have a role in selected cases such as recurrent pregnancy loss, but is not a routine first-line test and results vary by assay.
• Routine diagnostic laparoscopy: useful when endometriosis or adhesions are strongly suspected, but it is surgery, and it is not a screening test for everyone with infertility.
• Post-coital testing and routine endometrial biopsy dating: have largely fallen out of standard practice because they do not reliably guide treatment.

This is not an argument against specialised testing in the right context. It is an argument for sequence: answer the basic questions first, then escalate only where a specific finding or a failed treatment creates a specific question. If a proposed test is expensive, not covered by insurance, and would not alter the plan either way, asking for the evidence behind it is entirely appropriate.

13. Understanding Your Results: Normal, Borderline, and ‘Unexplained’

Results rarely arrive as a single clean verdict, and learning to read them realistically is part of the process. Four patterns are common.

• A clear, treatable cause. Ovulatory dysfunction from PCOS, a submucosal fibroid, a thyroid abnormality, or a tubal blockage. These findings are valuable precisely because they point to a specific intervention.
• A finding that changes the plan but not the diagnosis. Low ovarian reserve does not explain why conception has not occurred, but it does change how much time is reasonable to spend on low-intensity treatment.
• Borderline or discordant results. AMH low but AFC normal, one abnormal semen analysis followed by a normal one, HSG suggesting a proximal block that may be spasm. Discordance is common and often resolves with a carefully timed repeat rather than a major treatment decision.
• Unexplained infertility. A standard workup finds no cause. Published estimates of how common this is vary with how extensive the testing was and which definition is used; NICHD and ASRM patient resources describe it as a recognised outcome of a normal evaluation. It is a statement about the limits of current testing, not a claim that nothing is going on — and it is not a reason to keep ordering more tests indefinitely.

The practical implication of unexplained infertility is that treatment becomes empirical: moving from expectant management to ovulation induction with timed intercourse or IUI, and then to IVF if needed. IUI vs. IVF in Torrance compares those paths, including medication burden and time-to-pregnancy. NICHD’s treatment overview gives a neutral summary of the main options.

14. From Workup to Plan: Turning Findings Into a Decision

A useful results consultation ends with a written plan that names the findings, the reasoning, the recommended next step, and the criteria for changing course. Broadly, the mapping looks like this:

• Normal workup, younger patient, short duration of trying: expectant management with cycle timing may be reasonable, sometimes with a defined review point.
• Ovulatory dysfunction: ovulation induction with timed intercourse or IUI, addressing PCOS and metabolic factors in parallel.
• Mild male factor or unexplained infertility: often a limited number of IUI cycles before reassessment — a number worth agreeing on in advance rather than extending indefinitely.
• Bilateral tubal blockage or severe male factor: IVF, with ICSI for the latter; see Male Infertility and ICSI in Torrance.
• Diminished ovarian reserve or age-related time pressure: an earlier move to IVF, with an honest discussion of expected egg yield.
• Cavity lesion or distorting fibroid: surgical correction before transfer or insemination, with a defined waiting period before attempting pregnancy.
• Recurrent pregnancy loss: a distinct evaluation path; see Recurrent Pregnancy Loss in Torrance.

If the plan is IVF, our step-by-step IVF journey guide walks through stimulation, retrieval, transfer, and the two-week wait, while the IVF in Torrance overview explains how the pieces of treatment fit together. If the plan is to preserve options rather than treat immediately, Egg Freezing in Torrance covers fertility preservation as a planning tool rather than a guarantee. ACOG’s Treating Infertility FAQ provides a neutral patient-facing parallel.

Cost and coverage deserve a direct conversation during this consultation, not after it. Diagnostic testing, medications, procedures, and ART cycles are frequently billed and covered differently, and coverage varies by plan, employer, and state. ACOG explicitly notes that infertility testing may not be covered by insurance. Ask for a written estimate that itemises each component, and confirm pre-authorisation requirements in writing before scheduling. Any figures you see quoted online — including in general patient resources — are typical ranges, not a clinic quote, an estimate, or an offer, and should not be used for budgeting without a written assessment.

Practical Next Steps

1. Use the 12 / 6 / 3 rule to decide whether it is time to book an evaluation, and skip the waiting period if any of the earlier-listed risk factors apply.
2. Plan for both partners to attend the first appointment. The workup is faster, cheaper, and more informative when male and female testing happen in parallel.
3. Gather prior records and a cycle calendar before the visit, and ask which blood tests must be timed to a specific cycle day.
4. Ask for the rationale behind each ordered test: what decision will this result change?
5. Request a written summary of results and a written plan with a defined review point.
6. Clarify insurance coverage and get an itemised written estimate before any procedure.

If you would like to discuss an evaluation, our team can be reached through the fertility services page. The purpose of a workup is not to produce an alarming number — it is to replace uncertainty with a plan you can evaluate, question, and act on.

Frequently Asked Questions

How long does a fertility workup usually take?

Most of the basic evaluation can be completed within one to two menstrual cycles, roughly a few weeks. The timing constraint is that several tests are cycle-day dependent: baseline FSH and estradiol are drawn in the early follicular phase, mid-luteal progesterone about seven days before an expected period, and HSG is performed in the first half of the cycle. An abnormal semen analysis may need repeating after an interval reflecting the roughly two-to-three-month sperm production cycle. ACOG’s Evaluating Infertility FAQ addresses how long testing takes. Your clinic should be able to give you a written schedule rather than ordering tests piecemeal.

Do both partners need to be tested at the same time?

Yes, that is the standard recommendation. MedlinePlus notes that about half of couples unable to have children have a male infertility problem, and WHO classifies infertility causes as male, female, or unexplained. Semen analysis is non-invasive and relatively inexpensive compared with treatment, so deferring it while the female partner completes months of testing can waste the most useful early information. Parallel testing also shortens the time to a plan.

What is the difference between AMH and FSH?

Both relate to ovarian reserve, but they answer slightly different questions and have different practical constraints. AMH can be measured on any day of the cycle and correlates with the number of eggs likely to be retrieved during stimulation. FSH is drawn on cycle days 2 to 4 and must be interpreted alongside estradiol, because a high estradiol can make FSH look reassuringly normal. Antral follicle count on ultrasound provides a third, independent estimate. None of these tests predicts natural conception on its own. Our AMH and Ovarian Reserve in Torrance guide covers this in detail.

Is an HSG painful, and does it involve radiation?

HSG is an X-ray study using contrast dye, so it does involve low-dose ionising radiation and iodinated or water-soluble contrast. MedlinePlus describes cramping during and after the procedure, similar to menstrual cramps, and lists contrast allergy, endometrial or tubal infection, and rarely uterine perforation as risks. It is scheduled in the first half of the menstrual cycle and is not performed with active pelvic infection or unexplained vaginal bleeding. Tell your provider about any prior contrast reaction. Some patients use an over-the-counter analgesic beforehand; ask your clinic what it recommends.

What does ‘unexplained infertility’ actually mean?

It means a standard evaluation — ovulation, ovarian reserve, tubal patency, uterine cavity, and semen analysis — has not identified a cause. It is a statement about the limits of current testing, not proof that no problem exists, and published estimates of how often it occurs vary with how extensive the workup was. It generally does not mean more testing is the next step; it usually means moving to empirical treatment, such as a defined number of IUI cycles before considering IVF. NICHD and ASRM patient resources both describe unexplained infertility as a recognised diagnosis.

Will insurance cover fertility testing?

It depends on your plan, your employer, and your state, and diagnostic testing is often covered differently from treatment. ACOG’s Evaluating Infertility FAQ specifically notes that infertility testing is not always covered by insurance. Ask your insurer whether a referral or pre-authorisation is needed, and ask the clinic for an itemised written estimate before scheduling. Any cost figures quoted in general patient resources are typical ranges, not a clinic quote or an estimate, and should be confirmed in writing.

By the Incinta Editorial Team · Medically reviewed by the Incinta Review Team

Incinta Fertility Center — Fertility Clinic Torrance & South Bay, California